Company intelligence / Profile preview

CavoGene LifeSciences

Glen Burnie, Maryland, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

CavoGene LifeSciences is developing SynCav1, an AAV-based gene therapy that overexpresses neuron-targeted Caveolin-1; preclinical rodent models of amyotrophic lateral sclerosis, Alzheimer disease, aging, and neurotrauma have shown improved motor function, preserved body weight, extended survival, and enhanced learning, memory, and neuroplasticity, but no human clinical trials have yet been initiated.[7][8]

Therapeutic areas: Neurology
Modalities: Gene therapyAAV based gene therapy
Industry: Biotech

Partnerships

University of California San DiegoCSSi LifeSciences

Beyond the preview

Go deeper on CavoGene LifeSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CavoGene LifeSciences.

Explore the full profile